THE SEQIRUS PORTFOLIO OF INFLUENZA VACCINES 2019-2020 SEASON

Seqirus offers a wide range of influenza vaccines for patients 6 months to 65 years of age and older.

PACKAGING	AGES	PRESENTATION	DOSING	CPT* CODE	CARTON NDC #	SYRINGE/VIAL LABEL NDC #	PRODUCT DESCRIPTION
FLUAD influenza vaccine, adjuvanted 	65 years and older[1]	0.5 mL prefilled syringe†[1]	1 dose[1]	90653 (covered by Medicare Part B)	70461-019-03	70461-019-04	Trivalent influenza vaccine manufactured using **adjuvant technology**[1]
Influenza Vaccine FLUCELVAX QUADRIVALENT 	4 years and older[2]	5 mL multidose vial[2]	1 or 2 doses depends on vaccination history as per Advisory Committee on Immunization Practices annual recommendations on prevention and control of influenza with vaccines.[2]	90756	70461-419-10	70461-419-11	Quadrivalent influenza vaccine manufactured with **cell-based technology**[2]
Influenza Vaccine FLUCELVAX QUADRIVALENT 		0.5 mL prefilled syringe†[2]		90674	70461-319-03	70461-319-04	
INFLUENZA VACCINE afluria QUADRIVALENT 	6 months and older[3]	5 mL multidose vial	1 or 2 doses depends on vaccination history as per Advisory Committee on Immunization Practices annual recommendations on prevention and control of influenza with vaccines.[3]	90687 (0.25 mL dose) 90688 (0.5 mL dose)	33332-419-10	33332-419-11	Quadrivalent influenza vaccine manufactured with egg-based technology[3]
INFLUENZA VACCINE afluria QUADRIVALENT 	36 months and older	0.5 mL prefilled syringe†[3]		90686	33332-319-01	33332-319-02	
INFLUENZA VACCINE afluria QUADRIVALENT 	6 months through 35 months	0.25 mL prefilled syringe†[3]		90685	33332-219-20	33332-219-21	

Please see Important Safety Information for FLUAD, FLUCELVAX QUADRIVALENT, and AFLURIA QUADRIVALENT on the backside. Full US Prescribing Information located within.

Visit flu.seqirus.com for more information and to place your order.

*CPT=Current Procedural Terminology. †The prefilled syringes are free of preservatives.

References: 1. Fluad [package insert]. Summit, NJ: Seqirus USA Inc; 2018. **2.** Flucelvax Quadrivalent [package insert]. Summit, NJ: Seqirus USA Inc; 2018. **3.** Afluria Quadrivalent [package insert]. Summit, NJ: Seqirus USA Inc; 2018.

FLUAD® IMPORTANT SAFETY INFORMATION

INDICATIONS AND USAGE

FLUAD® (Influenza Vaccine, Adjuvanted) is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine. FLUAD is approved for use in persons 65 years of age and older.

CONTRAINDICATIONS

Severe allergic reaction to any component of the vaccine, including egg protein, or after a previous dose of any influenza vaccine.

WARNINGS AND PRECAUTIONS

- If Guillain-Barré syndrome (GBS) has occurred within six weeks of previous influenza vaccination, the decision to give FLUAD should be based on careful consideration of the potential benefits and risks.

ADVERSE REACTIONS

- The most common (≥10%) local (injection site) adverse reactions observed in clinical studies were injection site pain (25%) and tenderness (21%).
- The most common (≥10%) systemic adverse reactions observed in clinical studies were myalgia (15%), headache (13%), and fatigue (13%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 and www.vaers.hhs.gov.

For more information, please see US full Prescribing Information for FLUAD.

FLUAD® is a registered trademark of Seqirus UK Limited or its affiliates.

FLUCELVAX® QUADRIVALENT IMPORTANT SAFETY INFORMATION

Indication and Usage for FLUCELVAX® QUADRIVALENT (Influenza Vaccine)

FLUCELVAX QUADRIVALENT is an inactivated vaccine indicated for active immunization for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.

FLUCELVAX QUADRIVALENT is approved for use in persons 4 years of age and older.

Contraindications

- Do not administer FLUCELVAX QUADRIVALENT to anyone with a history of severe allergic reaction (e.g. anaphylaxis) to any component of the vaccine.

Warnings & Precautions

- Guillain-Barré Syndrome (GBS): If GBS has occurred within 6 weeks of receipt of a prior influenza vaccine, the decision to give FLUCELVAX QUADRIVALENT should be based on careful consideration of the potential benefits and risks.

Adverse Reactions

- The most common (≥10%) local and systemic reactions in adults 18-64 years of age were injection site pain (45.4%), headache (18.7%), fatigue (17.8%), myalgia (15.4%), injection site erythema (13.4%), and induration (11.6%).
- The most common (≥10%) local and systemic reactions in adults ≥65 years of age were injection site pain (21.6%) and injection site erythema (11.9%).
- The most common (≥10%) local and systemic reactions in children 4 to <6 years of age were tenderness at the injection site (46%), injection site erythema (18%), sleepiness (19%), irritability (16%), injection site induration (13%), and change in eating habits (10%).
- The most common (≥10%) local and systemic reactions in children 6 through 8 years of age were pain at the injection site (54%), injection site erythema (22%), injection site induration (16%), headache (14%), fatigue (13%), and myalgia (12%).
- The most common (≥10%) local and systemic reactions in children and adolescents 9 through 17 years of age were pain at the injection site (58%), headache (22%), injection site erythema (19%), fatigue (18%), myalgia (16%), and injection site induration (15%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Please see US Full **Prescribing Information** for FLUCELVAX QUADRIVALENT.

FLUCELVAX QUADRIVALENT is a registered trademark of Seqirus UK Limited or its affiliates.

AFLURIA® QUADRIVALENT (Influenza Vaccine) IMPORTANT SAFETY INFORMATION

INDICATION

AFLURIA QUADRIVALENT is an inactivated influenza vaccine indicated for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. AFLURIA QUADRIVALENT is approved for use in persons 6 months of age and older.

CONTRAINDICATIONS

- Severe allergic reactions (e.g., anaphylaxis) to any component of the vaccine including egg protein, or to a previous dose of any influenza vaccine.

WARNINGS AND PRECAUTIONS

- If Guillain-Barré Syndrome (GBS) has occurred within 6 weeks of previous influenza vaccination, the decision to give AFLURIA QUADRIVALENT should be based on careful consideration of the potential benefits and risks.
- Appropriate medical treatment and supervision must be available to manage possible anaphylactic reactions following administration of the vaccine.
- Immunocompromised persons may have a diminished immune response to AFLURIA QUADRIVALENT.

ADVERSE REACTIONS

- In adults 18 through 64 years, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain (≥40%). The most common systemic adverse events were myalgia and headache (≥20%).
- In adults 65 years of age and older, the most commonly reported injection-site adverse reaction when administered by needle and syringe was pain (≥20%). The most common systemic adverse event was myalgia (≥10%).
- In children 5 through 8 years, the most commonly reported injection-site adverse reactions when administered by needle and syringe were pain (≥50%), redness and swelling (≥10%). The most common systemic adverse event was headache (≥10%).
- In children 9 through 17 years, the most commonly reported injection-site adverse reactions when administered by needle and syringe were pain (≥50%), redness and swelling (≥10%). The most common systemic adverse events were headache, myalgia, and malaise and fatigue (≥10%).
- In children 6 months through 35 months of age, the most commonly reported injection-site reactions were pain and redness (≥20%). The most common systemic adverse events were irritability (≥30%), diarrhea and loss of appetite (≥20%).
- In children 36 through 59 months of age, the most commonly reported injection site reactions were pain (≥30%) and redness (≥20%). The most commonly reported systemic adverse events were malaise and fatigue, and diarrhea (≥10%).

The safety experience with AFLURIA (trivalent formulation) is relevant to AFLURIA QUADRIVALENT because both vaccines are manufactured using the same process and have overlapping compositions:

- In adults 18 through 64 years of age, the most commonly reported injection-site adverse reactions with AFLURIA (trivalent formulation) when administered by the PharmaJet Stratis Needle-Free Injection System were tenderness(≥80%), swelling, pain, redness(≥60%), itching(≥20%) and bruising (≥10%). The most common systemic adverse events were myalgia, malaise(≥30%), and headache(≥20%).

To report SUSPECTED ADVERSE REACTIONS, contact Seqirus USA Inc. at 1-855-358-8966 or VAERS at 1-800-822-7967 or www.vaers.hhs.gov.

Please see full Prescribing Information for AFLURIA QUADRIVALENT.

AFLURIA is a registered trademark of Seqirus UK Limited or its affiliates.
PharmaJet® and STRATIS® are registered trademarks of PharmaJet.

25 Deforest Ave, Summit, NJ 07901
July 2019 US/CORP/0619/0148

SEQIRUS, FLUAD, FLUCELVAX, and AFLURIA are registered trademarks of Seqirus UK Limited or its affiliates.
MF59 is a registered trademark of Novartis AG.

Seqirus™
A CSL COMPANY